ScreenerHero

AARDAardvark Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · aardvarktherapeutics.com
6.820USD+1.04%Mkt Cap: 149.25M $P/E: —

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therape…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap149.25M $
Enterprise Value55.71M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-57.59M $
Revenue/Share—
Last Price6.820 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees28
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.12
PEG—
EV/EBITDA-0.75
EV/Revenue—
P/S—
P/B1.72
EPS (TTM)-2.82
EPS (Forward)-2.78
52W Range
3.35024% of range17.94
52W High17.94 USD
52W Low3.350 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-54.01%
ROA-49.15%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-54.17M $
CapEx (TTM)95.00K $
FCF Margin—
FCF Yield-31.42%
Net Debt-73.19M $
Net Debt/EBITDA0.99
Balance Sheet
Debt/Equity0.00
Current Ratio12.63
Quick Ratio11.57
Book Value/Sh3.418 USD
Cash/Share3.375 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.3 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)14.50 USD
Upside (mean)+112.6%
Target Range3.000 USD – 45.00 USD
$3.000+112.6% to mean$45.00
# Analysts10
Ownership
Shares Out.21.88M
Float10.94M
Insiders16.12%
Institutions52.61%
Short Interest
Short Ratio1.7d
Short % Float4.46%
Short % Out.2.98%
Shares Short652.50K
Short (prev mo.)528.26K
Technical
SMA 505.823 (+17.1%)
SMA 2008.191 (-16.7%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)272.30K
Avg Vol (10d)136.93K
Technical Indicators
RSI (14)52.7
MACD0.1311
MACD Signal0.2588
MACD Hist.-0.1277
BB Upper7.969 USD
BB Middle6.754 USD
BB Lower5.539 USD
BB Width35.98%
ATR (14)0.8538 USD
Vol Ratio (20d)1.38x